Selective covalent targeting of SARS-CoV-2 main protease by enantiopure chlorofluoroacetamide

The coronavirus disease 2019 (COVID-19) pandemic has necessitated the development of antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main protease (M-pro) is a promising target for COVID-19 treatment. Here, we report an irreversible SARS-CoV-2 M-pro inhibitor possessing chlorofluoroacetamide (CFA) as a warhead for the covalent modification of M-pro. Ugi multicomponent reaction using chlorofluoroacetic acid enabled the rapid synthesis of dipeptidic CFA derivatives that identified 18 as a potent inhibitor of SARS-CoV-2 M-pro. Among the four stereoisomers, (R,R)-18 exhibited a markedly higher inhibitory activity against M-pro than the other isomers. Reaction kinetics and computational docking studies suggest that the R configuration of the CFA warhead is crucial for the rapid covalent inhibition of M-pro. Our findings highlight the prominent influence of the CFA chirality on the covalent modification of proteinous cysteines and provide the basis for improving the potency and selectivity of CFA-based covalent inhibitors.

Automated summary

This study reports an irreversible inhibitor of SARS-CoV-2 M-pro with chlorofluoroacetamide (CFA) as a covalent modification agent. The (R,R)-18 isomer showed higher inhibitory activity against M-pro than other isomers. The findings highlight the influence of CFA chirality on the covalent modification of proteinous cysteines and provide a basis for improving the potency and selectivity of CFA-based covalent inhibitors.